BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/15/2026 5:45:56 AM | Browse: 1 | Download: 2
 |
Received |
|
2026-03-17 02:30 |
|
Peer-Review Started |
|
2026-03-17 02:30 |
|
First Decision by Editorial Office Director |
|
2026-04-04 03:32 |
|
Return for Revision |
|
2026-04-04 03:32 |
|
Revised |
|
2026-04-15 03:21 |
|
Publication Fee Transferred |
|
2026-04-16 06:50 |
|
Second Decision by Editor |
|
2026-04-24 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-24 10:48 |
|
Articles in Press |
|
2026-04-24 10:48 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-10-08 00:16 |
|
Publish the Manuscript Online |
|
2026-10-15 05:45 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qi-Ming Zheng, Chi-Yi Chen, Li Zhang, Ji-San Sun, Hong-Hai Wang, Yan Xie, Qing-Jun Guo and Wen-Tao Jiang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Key Project of Tianjin Science and Technology Bureau Applied Basic Research |
No. 23JCZDJC01200 |
| Independent Research Fund of the Institute of Transplant Medicine at Nankai University |
No. NKTM2023004 |
| Tianjin Key Medical Discipline Construction Project |
No. TJYXZDXK-3-006A-1 |
|
| Corresponding Author |
Wen-Tao Jiang, MD, PhD, Principal Investigator, Department of Liver Transplantation, First Central Hospital of Tianjin Medical University, No. 2 Baoshan West Road, Xiqing District, Tianjin 300192, China. jiangwentao@nankai.edu.cn |
| Key Words |
Liver transplantation; Neuroendocrine tumors; Liver metastasis; Peptide receptor radionuclide therapy; Recurrence; Progression-free survival |
| Core Tip |
This retrospective comparative cohort study evaluates lutetium Lu 177 dotatate (177Lu-DOTATATE) peptide receptor radionuclide therapy (PRRT) combined with everolimus in somatostatin receptor-positive G2 neuroendocrine tumor liver metastases after liver transplantation. In 7 PRRT-treated patients vs 8 controls, PRRT achieved a disease control rate of 85.7% and significantly improved progression-free survival (log-rank P = 0.028), with manageable hematologic toxicity (grade III in 28.6%) and no graft rejection. These hypothesis-generating findings suggest PRRT as a promising option for this rare cohort. |
| Publish Date |
2026-10-15 05:45 |
| Citation |
Zheng QM, Chen CY, Zhang L, Sun JS, Wang HH, Xie Y, Guo QJ, Jiang WT. Peptide receptor radionuclide therapy for recurrent neuroendocrine tumors after liver transplantation. World J Gastroenterol 2026; 32(45): 121126
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i45/121126.htm |
| DOI |
https://doi.org/10.3748/wjg.121126 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
